Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) / Airlangga University, Biotis Pharma - LARVOL DELTA

UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects (clinicaltrials.gov) - P1 | N=250 | Active, not recruiting | Sponsor: Dr. Soetomo General Hospital

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study) (clinicaltrials.gov) - P1 | N=400 | Recruiting | Sponsor: Dr. Soetomo General Hospital

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Inactivated SARS-CoV-2 vaccine candidate immunization on non-human primate animal model: B-cell and T-cell responses immune evaluation. (PubMed, Heliyon) - "The dose of vaccine that produce adequate immune cell stimulation with neutralizing antibody induction can be adopted to clinical study, as favorable result of these parameters could predict minimum adverse reaction from inflammation response with balanced immune response. Therefore, it is concluded that Vaksin Merah Putih-INAVAC with 3 μg dose showed a favorable potential to be developed and tested as human vaccine."

Journal • Preclinical • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) (clinicaltrials.gov) - P1 | N=350 | Recruiting | Sponsor: Dr. Soetomo General Hospital

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

UNAIR Inactivated COVID-19 Vaccine Phase 3 (clinicaltrials.gov) - P3 | N=4005 | Recruiting | Sponsor: Dr. Soetomo General Hospital

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IL2 • TNFA

Newly added product (The Jakarta Post) - Preclinical, Novel Coronavirus Disease

Pipeline update